Moderna, Inc.
https://www.modernatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
Industry Leaderboard Gains And Dips Were Still Marked By COVID-19
Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
UK Biopharma Looks To Learn From Flagship Pioneering And Make ‘Bigger Leaps’
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
Worries And Hopes For Health Care Delivery In 2024
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice